These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

246 related items for PubMed ID: 30843348

  • 1. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer.
    Li C, Li T, Huang L, Yang M, Zhu G.
    Chem Asian J; 2019 May 02; 14(9):1570-1576. PubMed ID: 30843348
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Nanoparticle-Mediated Gene Silencing for Sensitization of Lung Cancer to Cisplatin Therapy.
    Feldmann DP, Heyza J, Zimmermann CM, Patrick SM, Merkel OM.
    Molecules; 2020 Apr 24; 25(8):. PubMed ID: 32344513
    [Abstract] [Full Text] [Related]

  • 4. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR, Arora S, Zhang H, Conner KL, Lei W, Floyd AM, Deshmukh RR, Sarver J, Trabbic CJ, Erhardt P, Chan TH, Dou QP, Patrick SM.
    Nutrients; 2018 Nov 03; 10(11):. PubMed ID: 30400270
    [Abstract] [Full Text] [Related]

  • 5. Platinum(iv) prodrugs with long lipid chains for drug delivery and overcoming cisplatin resistance.
    Chen Q, Yang Y, Lin X, Ma W, Chen G, Li W, Wang X, Yu Z.
    Chem Commun (Camb); 2018 May 22; 54(42):5369-5372. PubMed ID: 29744485
    [Abstract] [Full Text] [Related]

  • 6. Combination Chemotherapy of Lung Cancer - Co-Delivery of Docetaxel Prodrug and Cisplatin Using Aptamer-Decorated Lipid-Polymer Hybrid Nanoparticles.
    Wu R, Zhang Z, Wang B, Chen G, Zhang Y, Deng H, Tang Z, Mao J, Wang L.
    Drug Des Devel Ther; 2020 May 22; 14():2249-2261. PubMed ID: 32606595
    [Abstract] [Full Text] [Related]

  • 7. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
    He L, Liu K, Wang X, Chen H, Zhou J, Wu X, Liu T, Yang Y, Yang X, Cui D, Song G, Wang J, Lei J.
    Int J Biochem Cell Biol; 2018 Jul 22; 100():54-60. PubMed ID: 29768183
    [Abstract] [Full Text] [Related]

  • 8. Overcoming cisplatin resistance in non-small cell lung cancer with Mad2 silencing siRNA delivered systemically using EGFR-targeted chitosan nanoparticles.
    Nascimento AV, Singh A, Bousbaa H, Ferreira D, Sarmento B, Amiji MM.
    Acta Biomater; 2017 Jan 01; 47():71-80. PubMed ID: 27697601
    [Abstract] [Full Text] [Related]

  • 9. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X, Fan XF, Li Q, Liu S, Wu DY, Wang SY, Shi Y, Dong M.
    Oncol Rep; 2019 Mar 01; 41(3):1875-1882. PubMed ID: 30628719
    [Abstract] [Full Text] [Related]

  • 10. Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer.
    Mattheolabakis G, Ling D, Ahmad G, Amiji M.
    Pharm Res; 2016 Dec 01; 33(12):2943-2953. PubMed ID: 27528390
    [Abstract] [Full Text] [Related]

  • 11. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG, Pan ZY, Zhang DY, Cao Q, Ji LN, Mao ZW.
    ACS Appl Mater Interfaces; 2020 Sep 30; 12(39):43444-43455. PubMed ID: 32883070
    [Abstract] [Full Text] [Related]

  • 12. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM.
    DNA Repair (Amst); 2010 Jul 01; 9(7):745-53. PubMed ID: 20418188
    [Abstract] [Full Text] [Related]

  • 13. Overcoming tumor resistance to cisplatin by cationic lipid-assisted prodrug nanoparticles.
    Cao ZT, Chen ZY, Sun CY, Li HJ, Wang HX, Cheng QQ, Zuo ZQ, Wang JL, Liu YZ, Wang YC, Wang J.
    Biomaterials; 2016 Jul 01; 94():9-19. PubMed ID: 27088406
    [Abstract] [Full Text] [Related]

  • 14. Targeted iron nanoparticles with platinum-(IV) prodrugs and anti-EZH2 siRNA show great synergy in combating drug resistance in vitro and in vivo.
    Yu C, Ding B, Zhang X, Deng X, Deng K, Cheng Z, Xing B, Jin D, Ma P, Lin J.
    Biomaterials; 2018 Feb 01; 155():112-123. PubMed ID: 29175080
    [Abstract] [Full Text] [Related]

  • 15. Mitochondria-Targeted Multifunctional Nanoprodrugs by Inhibiting Metabolic Reprogramming for Combating Cisplatin-Resistant Lung Cancer.
    Lu H, Tong W, Jiang M, Liu H, Meng C, Wang K, Mu X.
    ACS Nano; 2024 Aug 13; 18(32):21156-21170. PubMed ID: 39088743
    [Abstract] [Full Text] [Related]

  • 16. [Enhancement effect of nucleotide excision repair gene xeroderma pigmentosun group a antisense RNA on sensitivity of human lung adenocarcinoma cell line A549 to cisplatin].
    Fan W, Zhang HL, Wu XM.
    Ai Zheng; 2005 Apr 13; 24(4):403-7. PubMed ID: 15820060
    [Abstract] [Full Text] [Related]

  • 17. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F, Tuszynski JA, Barakat KH.
    J Mol Graph Model; 2016 Apr 13; 65():71-82. PubMed ID: 26939044
    [Abstract] [Full Text] [Related]

  • 18. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
    Ai F, Sun T, Xu Z, Wang Z, Kong W, To MW, Wang F, Zhu G.
    Dalton Trans; 2016 Aug 16; 45(33):13052-60. PubMed ID: 27430044
    [Abstract] [Full Text] [Related]

  • 19. Imidazole modified Pt(iv) prodrug-loaded multi-stage pH responsive nanoparticles to overcome cisplatin resistance.
    Kang X, Wang Y, Chen Z, Wu Y, Chen H, Yang X, Yu C.
    Chem Commun (Camb); 2020 Sep 28; 56(76):11271-11274. PubMed ID: 32830841
    [Abstract] [Full Text] [Related]

  • 20. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells.
    Wu X, Fan W, Xu S, Zhou Y.
    Clin Cancer Res; 2003 Dec 01; 9(16 Pt 1):5874-9. PubMed ID: 14676109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.